The University of Chicago Header Logo

Connection

Julie Fitzgerald to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Julie Fitzgerald has written about Drug Resistance, Neoplasm.
Julie Fitzgerald
Connection Strength
0.149
Drug Resistance, Neoplasm
  1. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 03 10; 39(8):920-930.
    View in: PubMed
    Score: 0.149
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.